Results 171 to 180 of about 3,083,119 (212)
Some of the next articles are maybe not open access.

Psychiatric Residents’ Perspectives on Psychedelics and Psychedelic Assisted Therapy

Journal of Psychoactive Drugs
This study evaluated the attitudes, knowledge, and educational experiences of psychiatry residents regarding psychedelics and psychedelic-assisted therapy (PAT). In 2023, we distributed an anonymous survey to United States psychiatry residents, assessing demographics, knowledge, and opinions on psychedelics/PAT.
Brian S. Barnett   +6 more
openaire   +2 more sources

The phenomenology of psychedelic therapy

2021
‘The phenomenology of psychedelic therapy’ provides a selective overview of experiences commonly reported by those who take psychedelics in controlled and structured settings, such as clinical trials and religious rituals. The first half of this chapter reviews a variety of typical changes to perception and the sense of self.
openaire   +1 more source

The mechanisms of psychedelic therapy

2021
‘The mechanisms of psychedelic therapy’ presents arguments against three theories of psychedelic therapy. The Molecular Neuroplasticity Theory ascribes therapeutic benefits to an experience-independent molecular mechanism. This theory is undermined by the correlation between ‘mystical-type experiences’ and beneficial outcomes, which suggests that ...
openaire   +1 more source

Psychedelics in Psychiatry, the Nursing Influence, and the Future of Psychedelic Therapies

Journal of the American Psychiatric Nurses Association
OBJECTIVE: Psychedelics and psychedelic-assisted therapies (PATs) are on the cusp of becoming medicalized treatment modalities within the United States, both as potential U.S. Food and Drug Administration (FDA)-approved treatment and therapeutic options outside the medical model, through decriminalization ...
openaire   +2 more sources

Supportive Touch in Psychedelic Assisted Therapy

The American Journal of Bioethics
In August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.'s new drug application for midomafetamine with psychological intervention (MDMA-AT) to treat post-traumatic stress disorder (PTSD). Among the many issues raised during review was concern about a highly publicized case of alleged sexual misconduct by an unlicensed ...
Logan Neitzke-Spruill   +3 more
openaire   +2 more sources

Psychological Support Approaches in Psychedelic Therapy

The Journal of Clinical Psychiatry
Objective: To assess the viewpoints of psychedelic practitioners in research settings on approaches to psychological support for psychedelic treatments.Methods: An anonymous survey was distributed via email to contacts listed on ClinicalTrials.gov for clinical trials of psilocybin and LSD, personal contacts of authors, and through snowball sampling ...
David A, Bender   +5 more
openaire   +2 more sources

Informed Consent in Psychedelic-Assisted Therapy

Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings.
Mazdak M, Bradberry   +2 more
openaire   +2 more sources

Psychedelic Therapy for Depression

Depression affects over 280 million people worldwide and remains one of the leading causes of disability and suicide. Existing treatments such as SSRIs and traditional psychotherapy often fail to provide relief, especially for individuals with treatment‑resistant depression.
openaire   +2 more sources

The Broadening Scope of Oral Mucositis and Oral Ulcerative Mucosal Toxicities of Anticancer Therapies

Ca-A Cancer Journal for Clinicians, 2022
Stephen Sonis   +2 more
exaly  

Home - About - Disclaimer - Privacy